Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy arcticnovartis
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2026-02-13 08:19:142026-02-13 08:19:14Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy arcticnovartis
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2026-02-13 08:19:142026-02-13 08:19:14Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy arcticnovartis
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2026-02-13 08:19:142026-02-13 08:19:14Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
